Home Page
A Framework for Introducing Improved TB Vaccines to the World Community
This important international conference promises to be the premiere TB vaccine meeting of 2010.
New TB vaccines hold the promise of preventing TB globally and overcoming the challenges of drug-resistant TB and TB/HIV co-infection.
This scientific conference will include international experts chairing sessions on:
- Basic Research
- Applied Research
- Clinical Studies on TB Vaccines
- Manufacturing, Regulation and Vaccine Access
- Partnerships, Communication & Coordination
Participants will review progress on TB vaccines over the past ten years; assess challenges; propose solutions and reframe the global agenda for TB vaccines for the next decade.
Conference Dates: 21-24 September 2010
Conference Location: Tallinn, Estonia
New TB vaccines hold the promise of preventing TB globally and overcoming the challenges of drug-resistant TB and TB/HIV co-infection.
This scientific conference will include international experts chairing sessions on:
- Basic Research
- Applied Research
- Clinical Studies on TB Vaccines
- Manufacturing, Regulation and Vaccine Access
- Partnerships, Communication & Coordination
Participants will review progress on TB vaccines over the past ten years; assess challenges; propose solutions and reframe the global agenda for TB vaccines for the next decade.
Conference Dates: 21-24 September 2010
Conference Location: Tallinn, Estonia
| Date | |
| 12 July 2010 |
Final Date for Abstract Submissions |
| 1 September 2010 |
Registration Closes - All payments due in full |
| 21-24 September 2010 |
TB Vaccines: A Second Global Forum |
Advisory Panel
Chair:
Michael Brennan, Aeras Global TB Vaccine Foundation
Members:
Ulrich Fruth, World Health Organization
Jelle Thole, TuBerculosis Vaccine Initiative
Jan Gheuens, The Bill & Melinda Gates Foundation
Stefan H.E. Kaufmann, Max Planck Institute for Infection Biology
Greg Hussey, Institute of Infectious Disease & Molecular Medicine
Christine Sizemore, National Institutes of Health
Rick O’Brien, Foundation for Innovative New Diagnostics